Transcription of Brilinta Data sheet 190618 - Medsafe
{{id}} {{{paragraph}}}
Example: bachelor of science
Brilinta Data sheet 190618 - Medsafe
1. NEW ZEALAND DATA sheet . 1. PRODUCT NAME. BRILINTATM 60 mg film-coated tablets BRILINTATM 90 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. 60 mg: each tablet contains 60 mg ticagrelor. 90 mg: each tablet contains 90 mg ticagrelor. For a full list of excipients, see section 3. PHARMACEUTICAL FORM. 60 mg - Round, biconvex, pink, film coated tablets, marked with 60 above T on one side and plain on the other. 90 mg - Round, biconvex, yellow, film coated tablets, marked with 90' above T' on one side and plain on the other. 4. CLINICAL PARTICULARS. THERAPEUTIC INDICATIONS. Brilinta , co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke). in patients with Acute Coronary Syndromes (unstable angina [UA], non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]).
BRILINTA Data Sheet 190618 Copyright 3 Renal impairment No dose adjustment is necessary for patients with renal impairment (see section 5.2). Hepatic impairment No ...
Loading..
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: